Puma Biotechnology Inc
NASDAQ:PBYI
Intrinsic Value
Puma Biotechnology, Inc. is a biopharmaceutical company. [ Read More ]
The intrinsic value of one PBYI stock under the Base Case scenario is 4.92 USD. Compared to the current market price of 4.83 USD, Puma Biotechnology Inc is Undervalued by 2%.
Valuation Backtest
Puma Biotechnology Inc
Run backtest to discover the historical profit from buying and selling PBYI stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Puma Biotechnology Inc
Current Assets | 156.2m |
Cash & Short-Term Investments | 95.9m |
Receivables | 47.8m |
Other Current Assets | 12.4m |
Non-Current Assets | 74.3m |
PP&E | 8.6m |
Intangibles | 60.9m |
Other Non-Current Assets | 4.8m |
Current Liabilities | 99.4m |
Accounts Payable | 6.9m |
Accrued Liabilities | 57.5m |
Other Current Liabilities | 35m |
Non-Current Liabilities | 77.7m |
Long-Term Debt | 65.7m |
Other Non-Current Liabilities | 12m |
Earnings Waterfall
Puma Biotechnology Inc
Revenue
|
235.6m
USD
|
Cost of Revenue
|
-62.7m
USD
|
Gross Profit
|
173m
USD
|
Operating Expenses
|
-139.7m
USD
|
Operating Income
|
33.3m
USD
|
Other Expenses
|
-11.7m
USD
|
Net Income
|
21.6m
USD
|
Free Cash Flow Analysis
Puma Biotechnology Inc
PBYI Profitability Score
Profitability Due Diligence
Puma Biotechnology Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Puma Biotechnology Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
PBYI Solvency Score
Solvency Due Diligence
Puma Biotechnology Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Score
Puma Biotechnology Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PBYI Price Targets Summary
Puma Biotechnology Inc
According to Wall Street analysts, the average 1-year price target for PBYI is 4.42 USD with a low forecast of 2.02 USD and a high forecast of 7.35 USD.
Ownership
PBYI Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
PBYI Price
Puma Biotechnology Inc
Average Annual Return | -23.01% |
Standard Deviation of Annual Returns | 56.71% |
Max Drawdown | -95% |
Market Capitalization | 230.1m USD |
Shares Outstanding | 48 207 200 |
Percentage of Shares Shorted | 8.01% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Puma Biotechnology, Inc. is a biopharmaceutical company. The company is headquartered in Los Angeles, California and currently employs 196 full-time employees. The company went IPO on 2012-03-21. The firm is focused on the development and commercialization of products to enhance cancer care. The firm's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. The company is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one PBYI stock under the Base Case scenario is 4.92 USD.
Compared to the current market price of 4.83 USD, Puma Biotechnology Inc is Undervalued by 2%.